Lifeward Ltd. (Nasdaq: LFWD) has announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company reported a revenue of $5.1 million for Q4 2025, down from $7.5 million in Q4 2024, marking a decrease of approximately 33%. The revenue from the sale of ReWalk Personal exoskeletons increased by 20% to $1.8 million, driven by higher reimbursed unit sales. However, sales of the MyoCycle FES bike plummeted by 90% to $0.1 million, reflecting a strategic shift away from exclusive distribution arrangements. Lifeward's total revenue for the year was $22.0 million, down from $25.7 million in 2024, a decrease of 14%. Despite these challenges, the company reported a narrowing net loss of $5.3 million, or $3.60 per share, compared to a net loss of $15.3 million, or $20.82 per share, in the same quarter last year. The company has also made significant strides in operational efficiency, with total operating expenses in Q4 2025 declining by 64% to $6.2 million, primarily due to an impairment charge recognized in the previous year. Lifeward is advancing its transformation into a diversified biomedical innovation company, highlighted by a strategic agreement with Oramed Pharmaceuticals to acquire its Protein Oral Delivery (POD™) technology platform. This partnership is expected to provide a cash runway and position Lifeward on a clear path toward achieving cash flow positive. The company is also executing a strategic expansion through the acquisition of upper-body exoskeleton technology, which is anticipated to be ready for commercial launch within 18 to 24 months. Lifeward's focus on improving operational execution and expanding reimbursement coverage for its products is expected to drive growth in the coming quarters.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.